MorphoSys reports additional Phase II data for anti-CD19 mAb in DLBCL

MorphoSys AG (Xetra:MOR; Pink:MPSYY) reported data from 44 evaluable patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) in the Phase II L-MIND trial showing that

Read the full 288 word article

User Sign In